PLAUR and cancer: Various uPAR-targeted recombinant fusion toxins have been developed using the high-affinity catalytically inactive ATF1-135 of human uPA (containing the receptor binding domain, GFD) [176] as the molecular entity enabling the specific targeting of uPAR positive cancer cells [177].